Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Valneva ( (VALN) ) is now available.
Valneva reported audited 2025 results on March 18, 2026, posting total revenues of €174.7 million, including €157.9 million in product sales, as well as a widened net loss of €115.2 million largely due to the absence of a prior-year voucher gain. The group ended 2025 with €109.7 million in cash, reduced operating cash burn by 21%, refinanced debt, and confirmed 2026 guidance of €155–170 million in revenue and further cash-burn improvement while its main third-party distribution contract winds down.
Commercially, sales of IXIARO/JESPECT® rose on travel demand and a new U.S. Department of Defense contract, DUKORAL® was broadly stable, and IXCHIQ® revenue increased on European launches and outbreak response despite regulatory constraints and a voluntary withdrawal of U.S. filings in January 2026. Strategically, 2026 is positioned as a pivotal year, with Phase 3 data for Pfizer-partnered Lyme candidate VLA15 due in the first half and mid‑year Phase 2 data for Shigella vaccine S4V2, outcomes that could reshape Valneva’s pipeline, milestone inflows and long‑term competitive position in specialty vaccines.
The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a French specialty vaccine company listed on Nasdaq and Euronext Paris, focused on developing and commercializing prophylactic vaccines against infectious diseases, including Japanese encephalitis, cholera/ETEC diarrhea, chikungunya and Lyme disease, with a mix of proprietary products and partnered candidates targeting travelers, military and broader at‑risk populations.
Average Trading Volume: 18,873
Technical Sentiment Signal: Buy
Current Market Cap: $937.5M
See more insights into VALN stock on TipRanks’ Stock Analysis page.